Two AI‑focused protein design firms announced major financings to accelerate therapeutics and enzyme development. Profluent raised $106 million to expand large‑scale models for protein design and partner on enzyme development across therapeutics, agriculture and biomanufacturing. Iambic closed a $100 million round to advance multimodal clinical prediction and protein‑structure models (Enchant and NeuralPLexer) and to progress its brain‑penetrant oncology candidate into clinical stages. Both rounds signal continued investor appetite for AI platforms that shorten discovery cycles.